Actively Recruiting
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
Led by Yongquan Shi · Updated on 2025-07-02
400
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.
CONDITIONS
Official Title
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged from 18 to 75 years old.
- Diagnosed with OLGIM stage I to III gastric intestinal metaplasia by upper gastrointestinal endoscopy and histopathological exam within the last 3 months.
- Without Helicobacter pylori infection, including those who had successful eradication before enrollment.
You will not qualify if you...
- History of regular use (at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and/or statins.
- History of stomach surgery, including endoscopic submucosal dissection and endoscopic mucosal resection, or previously diagnosed malignant tumor.
- History of heart failure, renal failure, liver cirrhosis, or chronic hepatic failure.
- Contraindications or allergies to the study drugs.
- Currently pregnant or breastfeeding.
- History of substance abuse or alcohol abuse within the past year.
- Severe mental illness.
- Refusal to undergo drug treatment.
- Refusal to sign informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing hospital
Xi'an, China, 710032
Actively Recruiting
Research Team
Y
Yongquan Shi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here